echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The first innovative treatment approved in mainland China for glioblastoma in 15 years - Andding Pharmaceutical Epwed

    The first innovative treatment approved in mainland China for glioblastoma in 15 years - Andding Pharmaceutical Epwed

    • Last Update: 2020-05-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Guide: Epshield ® is the second product approved in mainland China within six monthsThe Ep Shield ® is the first innovative treatment approved for glioblastoma in mainland China in 15 years
    a large global phase 3 key clinical study for newly diagnosed glioblastoma shows that the chemotherapy-combined Epshield ® can more than double the total five-year survival rate of patients
    Ep shield ® is the second approved product in mainland China in six months
    MAY 14 /PRNEWSWIRE/ -- CHINA'S NATIONAL DRUG ADMINISTRATION (NMPA) HAS APPROVED A LISTING APPLICATION FOR TUMOR ELECTRIC FIELD TREATMENT OF EP SHIELD ® FOR TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS WITH TEMOLYNE AMINE, AS WELL AS FOR SINGLE THERAPY FOR PATIENTS WITH RELAPSED GLIOBLASTOMA, THE COMPANY ANNOUNCED TODAYGlioblastoma is the most common primary brain tumor, while Epshield ® is the first treatment approved for glioblastoma in mainland China in 15 yearsDrDu Ying, founder, chairman and chief executive officer ofAndding Pharmaceuticals, said, "The approval of the Epdin ® is another important milestone for Reeding Pharmaceuticals and has brought new hope for treatment for many glioblastoma patients in China." Earlier, Epshields was awarded the Right Toinnovateable Medical Device, highlighting its importance for patients with glioblastoma who have long lacked innovative treatmentsAs the world's original tumor electric field treatment technology, Epshield also has significant clinical application valueThe approval of Epshield also demonstrates the determination and speed of the National Drug Administration to focus on patients and speed up the review and approval of clinically urgently needed treatment programs, and has played a positive role in promoting the application of innovative technologies and the high-quality development of innovative industriesWilliam Doyle, executive chairman ofNovocure, said: "Through the continuous development and commercialization of this innovative technology for tumor electric field therapy, we hope to continue to extend the survival of patients with the most malignant types of tumorsGreater China has the largest number of glioblastoma patients in the world, and the approval of Epshield ® in this region is a further fulfillment of our commitment that tumor electric field treatment will benefit more patientsWe are very grateful to Retin Pharma for its efforts in this process and congratulate Retin Pharma on its second product launch approval in six months"
    Epshield ® has treated more than 15,000 glioblastoma patients worldwide by covering the electric field to specific areas for cancer treatment Tumor electric field treatment has also been approved by the U.S Food and Drug Administration (FDA) through the Humanitarian Equipment Waiver (HDE) approach for the treatment of malignant pleural mesothelioma (MPM), an indication that will then be submitted in the country In addition to glioblastoma and MPM, several key global Phase 3 clinical studies are being conducted to evaluate the efficacy of tumor electric field therapy for the treatment of brain metastasis, non-small cell lung cancer, pancreatic cancer and ovarian cancer, while Phase 2 clinical studies for liver and stomach cancer are also under way There are about 1.5 million newly diagnosed non-small cell lung, pancreatic, ovarian and stomach cancer patients in China each year "In China, more than 45,000 patients are diagnosed with glioblastoma each year, and treatment is very limited," said Jiang Tao, director of the Beijing Institute of Neurosurgery, director of the Beijing Institute of Neurosurgery and founder and founder of the China Glioma Genome Mapping Database (CGGA) and founder of Beijing Tiantan Hospital As the first new treatment in the field in more than a decade, Epshield ® has been included as A Grade 1 evidence in the Health and Reform Commission's first "Regulation synod for glioma diagnosis and treatment" (2018 edition) We look forward to it being standard treatment for glioblastoma patients, giving hope to more patients "
    on epshield ®
    Epshield ® is an innovative treatment for GBM by transferring a specific electric field to a specific tumor area, a non-invasive, interference with the filament division of tumor cells tumor electric field therapy is a tumor treatment that uses specific electric field frequencies to interfere with cell division, inhibit tumor growth and kill cancer cells affected by electric fields Tumor electric field therapy does not stimulate brain tissue or cause fever in brain tissue, but rather works with cancer cells in a specific size of split Tumor electric field therapy has minimal damage to healthy cells The most common adverse reaction is mild to moderate skin irritation Tumor electric field therapy has been approved in some countries and regions for the treatment of glioblastoma and mesothelioma in adult patients, one of the two most difficult types of cancer This therapy has shown good prospects in a variety of solid tumor treatments, including some of the most malignant types of cancer approved indications (China) Ep shield ® for recurrent glioblastoma (GBM) and newly diagnosed screen GBM for tissue pathology or imaging diagnosis at age 22 and over newly diagnosed GBM newly diagnosed GBM patients, Epshield sin ® were used in combination with TMZ after surgery and radiation therapy recurrent GBM the epidary GBM ® as a single treatment in patients with recurrent GBM Is on Reeding Pharmaceuticals Reeding Pharmaceuticals is an innovative biopharmaceutical company dedicated to providing innovative medicines for patients with cancer, autoimmune and infectious diseases in China and around the world The company's experienced team has partnered with the world's leading biopharmaceutical companies to create a range of innovative drugs to meet the rapid growth of the Chinese pharmaceutical market and unmet medical needs worldwide Retin Pharma has built an in-house team with strong drug research and transformation capabilities to build a pipeline of candidate drugs with international intellectual property rights The vision of Retin Pharmaceuticals is to become a fully integrated and innovative biopharmaceutical company that develops, manufactures and markets innovative products to promote the health and well-being of human beings around the world Responsible Editor: 37
    related labels: Shanghai , and Then Ding Medicine , Epdin 0
    0
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.